NFlection Therapeutics key facts
as of Oct 2026- Developer of topical therapies designed to address rare skin disorders associated with abnormal RAS pathway activity.
- NFlection Therapeutics is valued at approximately $156.0M as of Oct 2026, set at its later-stage round, Aug 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $65.5M across 3 recorded rounds; the latest was Seed Round ($4.0M) in Jul 2023.
- Notable investors include F-Prime Capital, Eight Roads, venBio, Children's Tumor Foundation, U.S. Department of Health and Human Services.
- NFlection Therapeutics has filed 4 Form Ds with the SEC since 2017, most recently Jul 2023 ($4.0M sold to 2 investors).
- Status: Privately Held (backing).
Valued at $156.0M at its later-stage round, Aug 2025. Nothing has traded since.
- ·Watch NFlection Therapeutics: the Monday email on marks, rounds and moves
NFlection Therapeutics funding rounds
3 roundsWho backs NFlection Therapeutics
5NFlection Therapeutics valuation
NFlection Therapeutics was valued at $156 million at its later-stage round in Aug 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has NFlection Therapeutics raised?
NFlection Therapeutics has raised $65.5 million in total; 3 of its rounds are on record, from 2016 on. The largest on record was a $4 million seed round in Jul 2023.
NFlection Therapeutics has filed 4 Form Ds with the SEC since 2017, most recently in Jul 2023 ($4 million sold to 2 investors).
NFlection Therapeutics investors
5 investors are on record for NFlection Therapeutics, including F-Prime Capital, Eight Roads, venBio and Children's Tumor Foundation. The seed round in Jul 2023 drew 2 investors.
About NFlection Therapeutics
Developer of topical therapies designed to address rare skin disorders associated with abnormal RAS pathway activity. The company offers MEK inhibitors applied to the skin, enabling patients with uncommon dermatological conditions to receive localized treatment focused on disease control.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2014
- Employees
- 6
- Website
- nflection.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.